Eritel B 40mg/25mg Tablet PR is a combination antihypertensive medication containing Telmisartan 40mg and Metoprolol Succinate 25mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and decreased myocardial oxygen demand. This combination is indicated for the treatment of hypertension, providing complementary mechanisms to achieve effective blood pressure control in patients who require dual therapy. Eritel B 40mg/25mg Tablet PR is formulated as a prolonged-release tablet to ensure consistent plasma concentrations and improve patient compliance with once-daily dosing. It is contraindicated in patients with severe bradycardia, cardiogenic shock, or known hypersensitivity to either component. Caution is advised in patients with diabetes, renal or hepatic impairment, and those with a history of bronchospastic diseases. Regular monitoring of blood pressure, heart rate, renal function, and electrolytes is recommended during therapy to optimize treatment outcomes and minimize adverse effects.